Sugi Predict

Sugi Predict / Compounds / SCHEMBL1739798

SCHEMBL1739798

SCHEMBL1739798

CC(C)(C)[Si](OC[C@@H]1CCC(=O)O1)(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMYD2 Q9NRG4 3/20 0.41
▸ CYP1A2 P05177 2/20 0.35
▸ TOP2A P11388 1/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PSEN1 P49768 1/20 0.33
▸ PSEN2 P49810 1/20 0.33
▸ APH1B Q8WW43 1/20 0.33
▸ NCSTN Q92542 1/20 0.33
▸ APH1A Q96BI3 1/20 0.33
▸ PSENEN Q9NZ42 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ GRM5 P41594 2/20 0.33
▸ GRM1 Q13255 1/20 0.33
▸ BACE1 P56817 1/20 0.32
▸ GRM2 Q14416 1/20 0.31
▸ CA1 P00915 1/20 0.30
▸ CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9128317 1.00 SMYD2 (0.41) SMYD2CYP1A2TOP2ACYP3A4HTT
SCHEMBL1740050 1.00 SMYD2 (0.41) SMYD2CYP1A2TOP2ACYP3A4HTT
SCHEMBL1117861 0.92 SMYD2 (0.40) SMYD2TOP2ACYP3A4HTTSMN1; SMN2
SCHEMBL52552 0.82 SMYD2 (0.40) SMYD2CYP3A4HTTSMN1; SMN2PSEN1
SCHEMBL29946810 0.82 SMYD2 (0.40) SMYD2CYP3A4HTTSMN1; SMN2PSEN1
SCHEMBL18026905 0.82 SMYD2 (0.40) SMYD2CYP3A4HTTSMN1; SMN2PSEN1
SCHEMBL9274167 0.81 TOP2A (0.40) SMYD2TOP2A
SCHEMBL9266676 0.81 TOP2A (0.40) SMYD2TOP2A
SCHEMBL28346561 0.79 SMYD2 (0.40) SMYD2CYP3A4HTTSMN1; SMN2PSEN1
SCHEMBL6412838 0.79 SMYD2 (0.41) SMYD2TOP2ACYP3A4HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122223-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2025-04-17 — — US disclosed
EP-4466072-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS Almac Discovery Limited (GB) 2024-11-27 — — EP disclosed
CN-118946566-A Heterocyclic compounds as ubiquitin-specific protease 7 inhibitors 阿尔麦克探索有限公司 2024-11-12 — — CN disclosed
CN-117881402-A Nucleotide and nucleoside therapeutic compositions, combinations, and uses related thereto 埃默里大学 2024-04-12 — — CN disclosed
WO-2023139241-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2023-07-27 — — WO disclosed
EP-4001283-A1 SUBSTITUTED AMINOTHIAZOLOPYRIMIDINEDIONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2022-05-25 — — EP disclosed
US-11180525-B2 Process for making 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2, 7-dione compounds useful for the treatment of virus infection HOFFMANN-LA ROCHE, INC. (US) 2021-11-23 — — US disclosed
EP-3294746-B1 SUBSTITUTED AMINOTHIAZOLOPYRIMIDINEDIONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2021-10-06 — — EP disclosed
CN-107445980-B 3-substituted 5-amino-6H-thiazolo [4,5-d ] pyrimidine-2, 7-dione compounds 豪夫迈·罗氏有限公司 2021-04-20 — — CN disclosed
CN-107592864-B Novel substituted aminothiazolopyrimidinediones for the treatment and prevention of viral infections 豪夫迈·罗氏有限公司 2021-04-16 — — CN disclosed
EP-1058686-A1 2'-FLUORONUCLEOSIDES EMORY UNIVERSITY (US) 2000-12-13 — — EP disclosed
US-6121431-A VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS B VIRUS MEDIVIR AB (SE) 2000-09-19 — — US disclosed
US-5952500-A VIRICIDES CAN BE USED IN THERAPEUTIC AND PROPHYLACTIC TREATMENT OF THE ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), INFECTIONS OF HUMAN IMMUNE DEFICIENCY VIRUSES, HEPATITIS B VIRUS, HERPES VIRUSES AND CANCER MEDIVIR AB (SE) 1999-09-14 — — US disclosed
WO-1999043691-A1 2'-FLUORONUCLEOSIDES EMORY UNIVERSITY (US) 1999-09-02 — — WO disclosed
US-5747473-A L-nucleoside analogues and pharmaceutical compositions MEDIVIR AB (SE) 1998-05-05 — — US disclosed
US-5576429-A HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRICIDE; ANTITUMOR AGENT MEDIVIR AB (SE) 1996-11-19 — — US disclosed
US-5473063-A Reacting 2,3-epoxy-butanediol/1,4-/(having protected hydroxyl groups) with an alpha allylic nucleophile yields 2-hydroxy-3-allyl-1,4-butanediol, then oxidatively cleaving the double bond, cyclization, halogenation, acetylation or oxyalkylation MEDIVIR AB (SE) 1995-12-05 — — US disclosed
US-5440040-A Drug for Aids therapy; viricides MEDIVIR AB (SE) 1995-08-08 — — US disclosed
US-5175267-A Stereoselective glycosylation of hetercyclic bases UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1992-12-29 — — US disclosed
WO-1989012061-A1 PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES MEDIVIR AB (SE) 1989-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180525-B2 Process for making 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2, 7-dione compounds useful for the treatment of virus infection DHPS, TYMS, DPYD SMYD2 3563/4885CYP1A2 309/4885TOP2A 1473/4885
US-20250122223-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, SENP7 SMYD2 3468/4885CYP1A2 1425/4885TOP2A 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.